Seikagaku Corp. (SKUNF)
4.68
-5.32
(-53.20%)
USD |
OTCM |
Apr 02, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 255.54M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -53.20% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 39.02% |
Profile
| Seikagaku Corp. manufactures pharmaceuticals and medical devices with glycoconjugates; specifically, glycosaminoglycans (GAG) such as hyaluronic acid; as well as enzymes that act on GAG. It operates through the following segments: Pharmaceuticals and Limulus Amebocyte Lysate (LAL). The Pharmaceuticals segment develops and supplies intra-articular injections for improving joint functions, cross-linked hyaluronate hydrogel for knee osteoarthritis, opthalmic surgical aids, and surgical aids for endoscopic mucosal resection. The LAL segment manufactures and sells endotoxin-detecting reagents in Japan and overseas. The company was founded on June 2, 1947 and is headquartered in Tokyo, Japan. |
| URL | http://www.seikagaku.co.jp |
| Investor Relations URL | N/A |
| HQ State/Province | Tokyo |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 30, 2023 |
Profile
| Seikagaku Corp. manufactures pharmaceuticals and medical devices with glycoconjugates; specifically, glycosaminoglycans (GAG) such as hyaluronic acid; as well as enzymes that act on GAG. It operates through the following segments: Pharmaceuticals and Limulus Amebocyte Lysate (LAL). The Pharmaceuticals segment develops and supplies intra-articular injections for improving joint functions, cross-linked hyaluronate hydrogel for knee osteoarthritis, opthalmic surgical aids, and surgical aids for endoscopic mucosal resection. The LAL segment manufactures and sells endotoxin-detecting reagents in Japan and overseas. The company was founded on June 2, 1947 and is headquartered in Tokyo, Japan. |
| URL | http://www.seikagaku.co.jp |
| Investor Relations URL | N/A |
| HQ State/Province | Tokyo |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 30, 2023 |